Search
Velmanase alfa
go.drugbank.com/drugs/DB12374ApprovedInvestigational[L39744] It was granted marketing authorization by the European Commission in March 2018 under the market name Lamzede [L39754] as the first human recombinant form of alpha-mannosidase for the treatment … Patients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex sugars in the body.
Tyrothricin
go.drugbank.com/drugs/DB13503ApprovedWithdrawndo exist [L4028]. … and 40% neutral linear gramicidins (where valine-gramicidin A is often the major gramicidin present, although the mixture composition can vary) [L4019, L4021, L4022].
Mixtures: Tyrothricin "Provita" comp. - Lutschtabletten1D09C3
go.drugbank.com/drugs/DB05121Experimentalclass II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing … 1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody.
Ingenol mebutate
go.drugbank.com/drugs/DB05013ApprovedWithdrawnPEP005 also has potent anti-leukemic effects, inducing apoptosis in myeloid leukemia cell lines and primary AML cells at nanomolar concentrations. … Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis.
Synonyms: Mebutato de ingenol, 3-AngeloylingenolNafarelin
go.drugbank.com/drugs/DB00666ApprovedInvestigationalNafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. … Nafarelin has been used in the treatments of central precocious puberty and endometriosis.
Calcium carbimide
go.drugbank.com/drugs/DB09116ApprovedWithdrawn[A31516] This drug was developed by Lederle Cyanamid Canada Inc and approved for marketing in Canada in 1959. The current status of calcium carbimide is cancelled post marketing.[L1113] … Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde.
Categories: Drugs Used in Addictive Disorders, Drugs Used in Alcohol DependenceSynonyms: Cyanamide, calcium salt (1:1), methanediimine, calcium salt (1:1)Diethyltoluamide
go.drugbank.com/drugs/DB11282ApprovedDEET products are largely designed to be applied directly to human skin, where the exact mechanisms of actions in which DEET is capable of repelling insects and causing toxicity to humans is still not … Diethyltoluamide (DEET) is the common active ingredient in many insect repellent products. It is widely used to repel biting pests such as mosquitoes and ticks.
Categories: Compounds used in a research, industrial, or household settingSynonyms: 3-methyl-N,N-diethylbenzamide, N,N-diethyl-m-toluamidePhenyltoloxamine
go.drugbank.com/drugs/DB11160ApprovedNevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient. … Although phenyltoloxamine's ability to potentiate the effects of analgesics may be explained in part by its chemical nature as a first-generation H1 antihistamine that is capable of crossing the blood-brain
Mixtures: Dologesic DFBordetella pertussis fimbriae 2/3 antigen
go.drugbank.com/drugs/DB10790ApprovedInvestigationalBordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct
Mixtures: Repevax Injektionssuspension in einer Fertigspritze, Covaxis Injektionssuspension in einer FertigspritzeSynonyms: Bordetella pertussis fimbriae 2/3 antigen, Bordetella pertussis fimbriae 2/3 vaccine, inactivatedSotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigationalfound to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. … [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.